上海市锦天城（深圳）律师事务所 关于 厦门特宝生物工程股份有限公司 2024 年限制性股票激励计划首次授予部分第一个归属期 归属条件成就及部分限制性股票作废相关事项 之 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 | 释义 | 3 | | --- | --- | | 正文 | 4 | | 一、本次归属、作废的批准与授权 | 4 | | 二、本次归属的具体情况 | 6 | | （一）归属期 | 6 | | （二）归属条件及成就情况 | 6 | | （三）本次激励计划首次授予部分第一个归属期可归属的具体情况 | 8 | | 三、本次作废的具体情况 | 9 | | 四、本次归属、作废的信息披露 | 9 | | 五、结论意见 | 9 | 上海市锦天城（深圳）律师事务所 关于 厦门特宝生物工程股份有限公司 2024 年限制性股票激励计划首次授予部分第一个归属期归属条 件成就及部分限制性股票作废相关事项 之 法律意见书 致：厦门特宝生物工程股份有限公司 上海市锦天城（深圳）律师事务所接受厦门特宝生物工程股份有限公司（ ...

证券简称：特宝生物 证券代码：688278 上海荣正企业咨询服务（集团）股份有限公司 关于 厦门特宝生物工程股份有限公司 2024 年限制性股票激励计划首次授予部分 第一个归属期归属条件成就相关事项 之 独立财务顾问报告 2025 年 9 月 | 一、释义 | 2 | | --- | --- | | 二、声明 | 3 | | 三、基本假设 | 4 | | 四、独立财务顾问意见 | 5 | | （一）本次限制性股票激励计划的审批程序 5 | | | （二）本激励计划首次授予部分第一个归属期符合归属条件的说明 6 | | | （三）结论性意见 9 | | | 五、备查文件及咨询方式 | 10 | | （一）备查文件 10 | | | （二）咨询方式 10 | | 一、释义 2 1. 上市公司、公司、特宝生物：指厦门特宝生物工程股份有限公司。 2. 股权激励计划、限制性股票激励计划、本激励计划、本计划：指《厦门特宝 生物工程股份有限公司 2024 年限制性股票激励计划（草案）》。 3. 限制性股票、第二类限制性股票：符合本激励计划授予条件的激励对象，在 满足相应的归属条件后分次获得并登记的本公司 A 股普通股股票。 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-035 厦门特宝生物工程股份有限公司 第九届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 二、监事会会议审议情况 表决结果：3 票同意，0 票反对，0 票弃权。 （一）审议通过《关于作废 2024 年限制性股票激励计划部分已授予尚未 归属的限制性股票的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《关于 2024 年限制性股票激励计划首次授予部分第一个归属期归属条件成就的 公告》（公告编号：2025-037）。 监事会认为：公司作废处理 2024 年限制性股票激励计划部分已授予尚未归 属的限制性股票符合《公司法》《证券法》《上市公司股权激励管理办法》等 法律法规及公司《2024 年限制性股票激励计划（草案）》的相关规定，不存在 损害公司及全体股东利益的情形。因此，监事会同意作废 2024 年限制性股票激 励计划部分已授予尚未归属的限制性股票。 表决结果：3 票同意，0 ...

厦门特宝生物工程股份有限公司 监事会 厦门特宝生物工程股份有限公司（以下简称"公司"）监事会根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、中国证监会《上市公司股权激励管理办法》（以下简 称"《管理办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上 市规则》"）、《科创板上市公司自律监管指南第 4 号——股权激励信息披露》 等相关法律、法规及规范性文件和《公司章程》的有关规定，对公司 2024 年限 制性股票激励计划（以下简称"本激励计划"）首次授予的限制性股票第一个归 属期归属名单进行审核，发表核查意见如下： 公司 2024 年限制性股票激励计划首次授予的限制性股票第一个归属期的 600 名激励对象，符合《公司法》《证券法》《管理办法》《上市规则》等法律 法规和规范性文件以及《公司章程》规定的任职资格和激励对象条件，符合本次 激励计划规定的激励对象范围，其作为公司本次限制性股票激励计划激励对象的 主体资格合法、有效，激励对象获授限制性股票的归属条件已成就。 综上所述，监事会同意公司为本次符合条件的 600 名激励对象办理归属，对 ...

证券代码：688278 证券简称：特宝生物 公告编号：2025-034 厦门特宝生物工程股份有限公司 第九届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 鉴于公司 2024 年限制性股票激励计划首次授予的激励对象中，存在 72 名 激励对象离职及 1 名激励对象绩效考核结果为"不胜任"，根据《上市公司股 权激励管理办法》《2024 年限制性股票激励计划（草案）》等相关规定和公司 2024 年第一次临时股东大会的授权，董事会同意公司作废 2024 年限制性股票 激励计划 165,700 股已授予尚未归属的限制性股票。 董事长孙黎先生、董事赖力平女士为本次限制性股票激励对象，与董事杨 英女士、蓝柏林先生、孙邃先生均为关联董事，对本议案回避表决。 表决情况：4 票同意，0 票反对，0 票弃权。 本议案在提交董事会审议前，已经薪酬与考核委员会审议通过（孙黎先生 回避表决）。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 1 《关于作废 2024 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]

Company Overview - Teabo Bioengineering Co., Ltd. is located in Xiamen, Fujian Province, established on August 7, 1996, and listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1][2] - The main business revenue composition includes antiviral drugs (86.85%), blood/cancer drugs (12.87%), and other (supplement) (0.27%) [1] Financial Performance - For the first half of 2025, Teabo Bio achieved operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%, and a net profit attributable to shareholders of 428 million yuan, a year-on-year increase of 40.60% [2] - Since its A-share listing, Teabo Bio has distributed a total of 577 million yuan in dividends, with 506 million yuan distributed over the past three years [2] Stock Performance - As of September 25, Teabo Bio's stock price increased by 2.08%, reaching 83.08 yuan per share, with a total market capitalization of 33.797 billion yuan [1] - Year-to-date, the stock price has risen by 14.20%, with a 4.46% increase over the last five trading days and a 14.94% increase over the last 60 days [1] Shareholder Information - As of June 30, the number of shareholders for Teabo Bio was 8,439, an increase of 13.00% from the previous period, while the average circulating shares per person decreased by 11.51% to 48,204 shares [2] - Among the top ten circulating shareholders, Huaxia SSE Sci-Tech Innovation 50 ETF and E Fund SSE Sci-Tech Innovation 50 ETF increased their holdings [2]

Group 1 - The core transaction of TEBIO involved a block trade of 245,700 shares, amounting to 19.9975 million yuan, with a transaction price of 81.39 yuan per share [1][2] - In the last three months, TEBIO has recorded a total of 12 block trades, with a cumulative transaction amount of 82.0902 million yuan [2] - The closing price of TEBIO on the day of the block trade was 81.39 yuan, reflecting a daily increase of 3.31% and a turnover rate of 0.68% [2][3] Group 2 - The latest margin financing balance for TEBIO is 1.469 billion yuan, with an increase of 17.9079 million yuan over the past five days, representing a growth rate of 1.23% [3] - TEBIO was established on August 7, 1996, with a registered capital of 406.8 million yuan [3]

9月24日，特宝生物大宗交易成交24.57万股，成交额1999.75万元，占当日总成交额的8.24%，成交价 81.39元，较市场收盘价81.39元持平。 | A 200 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 卖出营业部 | 是否为专场 | | 025-09-24 | 特宝生物 | 688278 | 81.39 1999.75 24.57 | 国泰海湾区委股份 | 全部屋名對貿易 | Ka | ...

Core Viewpoint - The A-share market is experiencing a significant rebound, particularly in the Sci-Tech Innovation Board, with the ETF Huatai-PineBridge (589120) showing a notable increase of 1.59% as of 13:54 on September 24, and attracting over 20 million yuan in net subscriptions within three trading days [1][3]. Group 1: ETF Performance - The Huatai-PineBridge Sci-Tech Innovation Drug ETF (589120) has seen strong performance, with most of its constituent stocks rising, including Teva Biopharma up over 3%, and several others like Zai Lab and Eucure Biopharma rising over 2% [3]. - The top ten constituent stocks of the ETF include notable companies such as RYSE Pharmaceuticals (688235) with a weight of 9.92% and a rise of 1.93%, and Eucure Biopharma (688578) with a weight of 8.03% and a rise of 2.27% [4]. Group 2: Market Dynamics - The National Healthcare Security Administration is set to hold a communication meeting in Beijing to discuss negotiations and pricing with companies, marking a significant innovation in this year's healthcare directory adjustments [5]. - The current innovation drug market is driven by the trend of "local innovation - global monetization," which is seen as a key support for the industry's growth [6]. - Analysts from Xinda Securities believe that the trend of innovation in the drug sector is not over, with expectations for continued growth in innovative drugs, medical devices, and AI healthcare [7]. Group 3: Industry Outlook - Tianfeng Securities highlights that the Chinese innovative drug industry has achieved significant results and is now globally competitive, entering a phase of self-sustainability through commercialization [8]. - The industry is supported by favorable policies, a well-structured talent pool, and a collaborative approach between academia and industry, which enhances the efficiency of drug development [9]. - The future outlook suggests that increasing innovation will further unlock commercial value, with China becoming one of the most efficient countries in the drug development process [10].